- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Tahir Amin: Lessons Learned from Allergan's Patent Transfer
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses lessons learned from Allergan's transfer of patents to a sovereign tribe.
Transcript:
What have we learned from Allergan’s transfer of patents to a sovereign tribe about patents in the United States?
Thankfully we’ve learned that the courts struck it down. They saw it for what it was, there was a decision in Texas where the judge called it for what it was, then the PTAB also said no, these [inter partes review, IPRs] will go ahead. Thankfully, we saw sense that a maneuver by Allergan to actually avoid its patents from being challenged was avoided.
Unfortunately, I think that’s just the tip of the iceberg. Companies have a whole toolbox of strategies and tricks that they use, and unfortunately, in a way they’ve undermined what the patent system was originally intended for. Now they use it for a defensive and business strategy; it’s no longer about a strategy for invention and progress.
Instead, it’s just as much about how to keep my competitors off the marketplace, how can I build my fences, how can I keep my profits at the highest, when, really, we should be allowing progress to happen in a different way. For anyone who is a free-market person, the way the patent system works today is antithetical to a free market.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Top 5 Most-Read Legal Articles of 2024
December 23rd 2024The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and addressing challenges like litigation, regulatory hurdles, and patent disputes that shape the competitive landscape of affordable biologics.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
